To Our Shareholders and Investors
We would like to take this opportunity to thank you for your continued support.
The Mochida Group has contributed to society by creating and delivering "unique products" to patients. While recognizing diversifying medical and health needs as a business opportunity and responding to changes in the business environment, we continue to create useful new drugs in our core pharmaceuticals business and enhance our drug discovery pipeline by incorporating new drug discovery modalities. In addition, we continue to focus on the biomaterials business based on alginic acid and the healthcare business.
The Mochida Group's long-term vision is "to grow as a distinctive life and health-related business group that is recognized globally for its value by meeting medical and health needs. We have formulated "Where We Want to Be in 2031," which embodies this long-term vision, and are developing our business with the goal of achieving sales of 140 billion yen and an operating margin of 15% by 2031.
We will continue to pursue our "unique" value and contribute to the health and welfare of mankind through our business activities. We look forward to your continued support.
Naoyuki Mochida
Representative Director, President